AU Patent

AU2021376286A1 — Raf inhibitor for treating low grade glioma

Assigned to Brigham and Womens Hospital Inc · Expires 2023-06-22 · 3y expired

What this patent protects

Described herein are methods and compositions for treating gliomas such as pediatric low grade glioma. In some embodiments, a herein described method of treating pediatric low grade glioma comprises administering to a subject in need thereof (R)-2-(1-(6-amino-5-chloropyrimidine-4…

USPTO Abstract

Described herein are methods and compositions for treating gliomas such as pediatric low grade glioma. In some embodiments, a herein described method of treating pediatric low grade glioma comprises administering to a subject in need thereof (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (Compound A), or a pharmaceutically acceptable salt thereof. In some embodiments, Compound A or a pharmaceutically acceptable salt thereof is administered in an amount that is equivalent to about 400 mg/m

Drugs covered by this patent

Patent Metadata

Patent number
AU2021376286A1
Jurisdiction
AU
Classification
—
Expires
2023-06-22
Drug substance claim
No
Drug product claim
No
Assignee
Brigham and Womens Hospital Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.